Tofacitinib 5 MG

( DrugBank: Tofacitinib / KEGG DRUG: Tofacitinib citrate, Tofacitinib )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1
40Takayasu arteritis1
46Malignant rheumatoid arthritis5
IDDisease name (Link within this page)Number of trials
50Dermatomyositis3
271Ankylosing spondylitis9

11. Myasthenia gravis


Clinical trials : 439Drugs : 223 - (DrugBank : 73) / Drug target genes : 50 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

40. Takayasu arteritis


Clinical trials : 30Drugs : 41 - (DrugBank : 22) / Drug target genes : 26 - Drug target pathways : 115 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

50. Dermatomyositis


Clinical trials : 231Drugs : 216 - (DrugBank : 55) / Drug target genes : 59 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 603Drugs : 302 - (DrugBank : 69) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries